文献速递支持与姑息治疗

儿童癌症幸存者的加速衰老:慢性疾病的早发与超额风险

Accelerated Aging in Survivors of Childhood Cancer-Early Onset and Excess Risk of Chronic Conditions.
PubMed 文献 · JAMA Oncol · 2025-01-01

该模拟建模研究利用儿童癌症幸存者研究和国家数据库,预测1970至1999年确诊的5年幸存者终生罹患8种治疗相关癌症和心血管疾病的风险。幸存者发生至少一种疾病比一般人群提前17.7年,至65岁时55%的幸存者预计发生至少一种疾病,相对风险为2.7倍,绝对超额风险为34.2%。

要点

  • 5年幸存者达到20%发生至少一种疾病阈值的中位年龄为47.3岁,一般人群为65.0岁。
  • 至65岁时,55%幸存者预计发生至少一种疾病,相对风险为一般人群的2.7倍。
  • 接受放疗者发病提前22.0年,未接受放疗者仍提前13.5年。

核心结论

  • 儿童癌症幸存者发生衰老相关疾病的时间提前,且与既往是否接受放疗无关。
  • 作者认为这些发现强调应将幸存者的癌症和心血管疾病预防优先于一般人群数十年。

研究设计与样本

  • 模拟建模研究,利用儿童癌症幸存者研究及国家数据库数据,预测1970至1999年确诊的5年幸存者的长期结局。
  • 一般人群对照通过年龄、性别和日历年匹配的个体模拟,这些个体仅面临年龄相关风险。
  • 暴露因素包括治疗年代(1970年代、1980年代、1990年代)、原发癌症诊断和针对原发诊断的放疗(任何放疗、无放疗)。

主要发现

  • 一般人群中20%在65.0岁前发生至少一种疾病;5年幸存者中该阈值在47.3岁达到,发病提前17.7年(95%不确定性区间[UI],14.0-21.0)。
  • 至65岁时,55%的幸存者预计发生至少一种疾病,相对风险为一般人群的2.7倍(95% UI,2.2-3.5),绝对超额风险为34.2%(95% UI,28.3-42.5)。
  • 接受放疗者发病提前22.0年(95% UI,18.0-25.0),超额风险为37.3%(95% UI,31.6%-44.7%)。
  • 未接受放疗者发病提前13.5年(95% UI,10.0-16.0),超额风险为31.0%(95% UI,23.9%-40.3%)。
  • 达到40岁的幸存者与一般人群相比,10年内发生新疾病的风险为6.2倍(95% UI,4.8-9.4)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The lifetime risk of aging-related diseases among survivors of childhood cancer, accelerated by cancer treatment exposures, is unknown. Understanding this risk can provide a more comprehensive assessment of long-term health across the lifespan of survivors and guide adult care. OBJECTIVE: To estimate the lifetime risks of 8 treatment-related cancers and cardiovascular conditions among childhood cancer survivors and compare them with the general population. DESIGN, SETTING, PARTICIPANTS: Using data from the Childhood Cancer Survivor Study and national databases, this simulation modeling study projected long-term outcomes for 5-year survivors diagnosed between 1970 and 1999 based on treatment exposures and age-related risks. The general population comparator was simulated using age-, sex-, and calendar year-matched individuals who faced only age-related risks. EXPOSURES: Treatment era (1970s, 1980s, 1990s), original cancer diagnosis, radiation treatment for primary diagnosis (any, none). MAIN OUTCOMES AND MEASURES: Estimated lifetime risks of 8 health conditions (breast cancer, colorectal cancer, glial tumors, sarcomas, heart failure, coronary heart disease/myocardial infarction, stroke, and valvular disease). Risks were projected and compared with the general population, stratified by radiation exposure. RESULTS: In the general population, 20% developed at least 1 health condition by age 65.0 years; in 5-year survivors this threshold was reached at age 47.3 years, representing a 17.7-year (95% uncertainty interval [UI], 14.0-21.0) acceleration in disease onset. By age 65 years, 55% of survivors were projected to develop at least 1 condition, indicating a 2.7-fold (95% UI, 2.2-3.5) higher relative risk and 34.2% (95% UI, 28.3-42.5) absolute excess risk compared with the general population. Risks were higher among those treated with radiation therapy for childhood cancer (22.0 years earlier onset [95% UI, 18.0-25.0]; 37.3% excess risk [95% UI, 31.6%-44.7%]) but still elevated for those without radiation exposure (13.5 years earlier onset [95% UI, 10.0-16.0]; 31.0% excess risk [95% UI, 23.9%-40.3%]). Reaching middle age was still associated with increased health risks. Compared with the general population, survivors who reached age 40 years had a 6.2-fold higher risk (95% UI, 4.8-9.4) of developing a new condition within 10 years. CONCLUSIONS AND RELEVANCE: This study found that survivors of childhood cancer experience accelerated onset of aging-related diseases, regardless of prior radiation exposure. These findings underscore the importance of prioritizing cancer and cardiovascular disease prevention among survivors decades earlier than for the general population.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Yeh JM, Ward ZJ, Stratton KL, et al. Accelerated Aging in Survivors of Childhood Cancer-Early Onset and Excess Risk of Chronic Conditions. JAMA Oncol. 2025. PMID: 40111318. doi:10.1001/jamaoncol.2025.0236

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。